Table III.

GRADE summary of findings: effect of desvenlafaxine on QT interval in adults with mental disorders

Outcome		Risk with intervention per 1000	Risk with comparator per 1000	Relative measure of association	No. of participants (studies)	Quality (GRADE)	Comments†
Adults with major depressive disorder:
	QT prolonged, desvenlafaxine 50 mg/day	0	7	RR = 0.17 (0.01–4.07)	427 (1 RCT) [110]	Very low	No difference
	QTcF change, desvenlafaxine 200 mg/day	NR	NR	MD = 1.50 (–0.88 – 3.88)	2476 (4 RCTs) [115]	Low	No difference
	QTcF change, desvenlafaxine 600 mg/day	NR	NR	MD = –2.43 (–4.90 – 0.04)	2476 (4 RCTs) [115]	Low	No difference
Postmenopausal women with moderate to severe vasomotor symptoms:
	QT prolonged	1	0	RR = 2.96 (0.12–72.59)	2118 (1 RCT) [90]	Very low	No difference
Adults with painful diabetic peripheral neuropathy:
Ventricular tachycardia		3	0	RR = 0.85 (0.03–20.57)	412 (2 RCTs) [93]	Low	No difference

Population: adults with mental disorders, Settings: any, Intervention: desvenlafaxine, Comparator: placebo or no active drug. ^†We concluded that there is no difference in outcomes between active and control interventions based on p-value > 0.05 and inability to reject null hypotheses but without post hoc analysis of the statistical power to detect true differences.